Molecular pathogenesis of chronic myeloid leukaemia

Expert Reviews in Molecular Medicine

Volumn 5, Issue 27, 2003, Pages

  Smith, Duncan L ^a   Burthem, John ^a   Whetton, Anthony D ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BCR ABL; chronic myeloid leukaemia; CML; protein tyrosine kinase; translocation

Indexed keywords

BCR ABL PROTEIN;

BIOLOGICAL MODEL; BLOOD; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME MAP; CHRONIC MYELOID LEUKEMIA; GENE TRANSLOCATION; GENETICS; HEMATOPOIESIS; HUMAN; METABOLISM; ONCOGENE; PATHOLOGY; REVIEW;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; FUSION PROTEINS, BCR-ABL; GENES, ABL; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MODELS, BIOLOGICAL; TRANSLOCATION, GENETIC;

EID: 84867545531     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399403006835     Document Type: Review

References (216)

1. Shinton, N.K., ed. (1998) CRC Desk Reference for Hematology, CRC Press, Boca Raton
2. Virchow, R. (1845) Weisses Blut. Froiep's Notizen 36, 151
3. Bennett, J. (1845) Case of hypertrophy of the spleen and liver, in which death took from suppuration of the blood. Edinburgh Med. Surg. 64, 313
4. Savage, D.G., Szydlo, R.M. and Goldman, J.M. (1997) Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 96, 111-116, PubMed: 9012696
5. Ichimaru, M., Ishimaru, T. and Belsky, J.L. (1978) Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950-71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J Radiat Res (Tokyo) 19, 262-282, PubMed: 739446 (Pubitemid 9070651)
6. Court Brown, W.M. and Doll, R. (1959) Adult leukemia. Br Med J 1, 1063
7. Court Brown, W.M. and Doll, R. (1960) Adult Leukemia. Br Med J 1, 1753
8. Boice, J.D., Jr. et al. (1985) Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 74, 955-975, PubMed: 3858584 (Pubitemid 15062953)
9. Bjork, J. et al. (2001) Are occupational, hobby, or lifestyle exposures associated with Philadelphia chromosome positive chronic myeloid leukaemia? Occup Environ Med 58, 722-727, PubMed: 11600728 (Pubitemid 33010490)
10. Bortin, M.M. et al. (1987) HLA associations with leukemia. Blood 70, 227-232, PubMed: 3474040 (Pubitemid 17111266)
11. Posthuma, E.F. et al. (1999) HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 93, 3863-3865, PubMed: 10339494 (Pubitemid 29249834)
12. Posthuma, E.F. et al. (2000) HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia 14, 859-862, PubMed: 10803518 (Pubitemid 30235064)
13. Gunz, F.W. (1977) The epidemiology and genetics of the chronic leukaemias. Clin Haematol 6, 3-20, PubMed: 334415
14. Vickers, M. (1996) Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br J Haematol 94, 1-4, PubMed: 8757501 (Pubitemid 26232532)
15. Jaffe, E.S. et al. (2001) Chronic myeloproliferative diseases. In Tumours of the Haematopoietic and Lymphoid Tissues (World Health Organisation Classification of Tumours) (Jaffe, E.S. et al., eds), pp. 15-42, IARC Press, Lyon
16. Cervantes, F. et al. (1998) 'Lymphoid' blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. Br J Haematol 100, 123-128, PubMed: 9450800 (Pubitemid 28051849)
17. Kantarjian, H.M. et al. (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83, 445-454, PubMed: 3477958
18. Kantarjian, H.M. and Talpaz, M. (1988) Definition of the accelerated phase of chronic myelogenous leukemia. J Clin Oncol 6, 180-182, PubMed: 3422090
19. Kantarjian, H.M. and Talpaz, M. (1998) Questions raised by the Benelux CML Study Group: results from the randomized study with hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha2b for chronic myeloid leukemia. Blood 92, 2984-2987, PubMed: 9763593 (Pubitemid 28469123)
20. Nowell, P. and Hungerford, D. (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497
21. Rowley, J.D. (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290-293, PubMed: 4126434
22. Kurzrock, R., Gutterman, J.U. and Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319, 990-998, PubMed: 3047582
23. Collins, S.J. et al. (1984) Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells. Science 225, 72-74, PubMed: 6587568 (Pubitemid 14123413)
24. Gale, R.P. and Canaani, E. (1984) An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci USA 81, 5648-5652, PubMed: 6091099 (Pubitemid 14023822)
25. Groffen, J. et al. (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93-99, PubMed: 6319012 (Pubitemid 14155374)
26. Heisterkamp, N. et al. (1985) Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315, 758-761, PubMed: 2989703 (Pubitemid 15022931)
27. Daley, G.Q., Van Etten, R.A. and Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247, 824-830, PubMed: 2406902
28. de Klein, A. et al. (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765-767, PubMed: 6960256 (Pubitemid 13224358)
29. Heisterkamp, N. et al. (1983) Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306, 239-242, PubMed: 6316147 (Pubitemid 14232351)
30. Melo, J.V. et al. (1993) The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81, 158-165, PubMed: 8417787 (Pubitemid 23013690)
31. Melo, J.V. et al. (1994) P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia 8, 208-211, PubMed: 8289491
32. Pane, F. et al. (1996) Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 88, 2410-2414, PubMed: 8839830 (Pubitemid 26327488)
33. Sinclair, P.B. et al. (2000) Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95, 738-743, PubMed: 10648381
34. Huntly, B.J. et al. (2001) Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98, 1732-1738, PubMed: 11535505
35. Daley, G.Q. and Baltimore, D. (1988) Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci USA 85, 9312-9316, PubMed: 3143116 (Pubitemid 19001887)
36. Laneuville, P. et al. (1992) Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 80, 1788-1797, PubMed: 1327283
37. Pierce, A. et al. (1998) p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene 17, 667-672, PubMed: 9704934 (Pubitemid 28401036)
38. Pierce, A. et al. (2000) Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. Oncogene 19, 5487-5497, PubMed: 11114726 (Pubitemid 32000916)
39. Gishizky, M.L. and Witte, O.N. (1992) BCR/ABL enhances growth of multipotent progenitor cells but does not block their differentiation potential in vitro. Curr Top Microbiol Immunol 182, 65-72, PubMed: 1490392 (Pubitemid 23018866)
40. McLaughlin, J., Chianese, E. and Witte, O.N. (1987) In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome. Proc Natl Acad Sci USA 84, 6558-6562, PubMed: 3498165
41. Young, J.C. and Witte, O.N. (1988) Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures. Mol Cell Biol 8, 4079-4087, PubMed: 3263566
42. Zhao, R.C. et al. (1997) Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood 90, 4687-4698, PubMed: 9389683 (Pubitemid 28007180)
43. Holyoake, T.L. et al. (2002) Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 16, 549-558, PubMed: 11960331 (Pubitemid 34449732)
44. Holyoake, T.L. et al. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97, 720-728, PubMed: 11157490 (Pubitemid 32113406)
45. Gishizky, M.L., Johnson-White, J. and Witte, O.N. (1993) Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice. Proc Natl Acad Sci USA 90, 3755-3759, PubMed: 8475126 (Pubitemid 23111446)
46. Pear, W.S. et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemialike myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780-3792, PubMed: 9808572 (Pubitemid 28525205)
47. Zhang, X. and Ren, R. (1998) Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 92, 3829-3840, PubMed: 9808576 (Pubitemid 28525209)
48. McWhirter, J.R., Galasso, D.L. and Wang, J.Y. (1993) A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol 13, 7587-7595, PubMed: 8246975 (Pubitemid 23354283)
49. Pendergast, A.M. et al. (1991) BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell 66, 161-171, PubMed: 1712671 (Pubitemid 121001356)
50. Hawk, N. et al. (2002) Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354. Cancer Res 62, 386-390, PubMed: 11809685 (Pubitemid 34106409)
51. Laneuville, P. (1995) Abl tyrosine protein kinase. Semin Immunol 7, 255-266, PubMed: 8520030
52. Reuther, G.W. et al. (1994) Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science 266, 129-133, PubMed: 7939633 (Pubitemid 24345335)
53. Morrison, D. (1994) 14-3-3: modulators of signaling proteins? Science 266, 56-57, PubMed: 7939645 (Pubitemid 24345324)
54. Liu, J. et al. (1996) Inhibition of Bcr serine kinase by tyrosine phosphorylation. Mol Cell Biol 16, 998-1005, PubMed: 8622703 (Pubitemid 26061671)
55. Denhardt, D.T. (1996) Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling. Biochem J 318 (Pt 3), 729-747, PubMed: 8836113 (Pubitemid 26320934)
56. Montaner, S. et al. (1998) Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem 273, 12779-12785, PubMed: 9582304 (Pubitemid 28246832)
57. Diekmann, D. et al. (1991) Bcr encodes a GTPase-activating protein for p21rac. Nature 351, 400-402, PubMed: 1903516 (Pubitemid 21896606)
58. Bassermann, F. et al. (2002) Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway. J Biol Chem 277, 12437-12445, PubMed: 11790798 (Pubitemid 34952818)
59. Ma, G. et al. (1997) Bcr phosphorylated on tyrosine 177 binds Grb2. Oncogene 14, 2367-2372, PubMed: 9178913 (Pubitemid 27260729)
60. Pendergast, A.M. et al. (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75, 175-185, PubMed: 8402896 (Pubitemid 23306031)
61. Wu, Y., Liu, J. and Arlinghaus, R.B. (1998) Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase. Oncogene 16, 141-146, PubMed: 9467953 (Pubitemid 28043518)
62. Li, S. et al. (2001) Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling. Embo J 20, 6793-6804, PubMed: 11726515 (Pubitemid 33134209)
63. Scott, M.L. et al. (1991) v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc Natl Acad Sci USA 88, 6506-6510, PubMed: 1862078 (Pubitemid 21914975)
64. Van Etten, R.A., Jackson, P. and Baltimore, D. (1989) The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 58, 669-678, PubMed: 2670246 (Pubitemid 19210961)
65. Wetzler, M. et al. (1993) Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 92, 1925-1939, PubMed: 8408645 (Pubitemid 23304562)
66. Feller, S.M. et al. (1994) SH2 and SH3 domains as molecular adhesives: the interactions of Crk and Abl. Trends Biochem Sci 19, 453-458, PubMed: 7855886 (Pubitemid 24342756)
67. Pawson, T. and Gish, G.D. (1992) SH2 and SH3 domains: from structure to function. Cell 71, 359-362, PubMed: 1423600
68. Konopka, J.B. et al. (1984) Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity. J Virol 51, 223-232, PubMed: 6610061 (Pubitemid 14081259)
69. Kipreos, E.T. and Wang, J.Y. (1992) Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA. Science 256, 382-385, PubMed: 1566087
70. Heisterkamp, N. et al. (2000) Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants. Blood 96, 2226-2232, PubMed: 10979970
71. McWhirter, J.R. and Wang, J.Y. (1993) An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. Embo J 12, 1533-1546, PubMed: 8467803 (Pubitemid 23112807)
72. Nagar, B. et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859-871, PubMed: 12654251 (Pubitemid 36378887)
73. Pluk, H., Dorey, K. and Superti-Furga, G. (2002) Autoinhibition of c-Abl. Cell 108, 247-259, PubMed: 11832214 (Pubitemid 34161144)
74. Renshaw, M.W., Lewis, J.M. and Schwartz, M.A. (2000) The c-Abl tyrosine kinase contributes to the transient activation of MAP kinase in cells plated on fibronectin. Oncogene 19, 3216-3219, PubMed: 10918577 (Pubitemid 30455934)
75. Lewis, J.M. and Schwartz, M.A. (1998) Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem 273, 14225-14230, PubMed: 9603926 (Pubitemid 28319134)
76. Welch, P.J. and Wang, J.Y. (1993) A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell 75, 779-790, PubMed: 8242749 (Pubitemid 23346375)
77. Duyster, J., Baskaran, R. and Wang, J.Y. (1995) Src homology 2 domain as a specificity determinant in the c-Abl-mediated tyrosine phosphorylation of the RNA polymerase II carboxyl-terminal repeated domain. Proc Natl Acad Sci USA 92, 1555-1559, PubMed: 7533294
78. Afar, D.E. et al. (1995) Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci USA 92, 9540-9544, PubMed: 7568169
79. Mattioni, T. et al. (1995) Cell cycle arrest by tyrosine kinase Abl involves altered early mitogenic response. Oncogene 10, 1325-1333, PubMed: 7731683
80. Sawyers, C.L. et al. (1994) The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell 77, 121-131, PubMed: 7512450 (Pubitemid 24184693)
81. Yuan, Z.M. et al. (1997) Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 94, 1437-1440, PubMed: 9037071
82. Yuan, Z.M. et al. (1996) Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature 382, 272-274, PubMed: 8717045
83. Pandita, T.K. (2003) A multifaceted role for ATM in genome maintenance.Exp. Rev. Mol. Med. Vol. 5, 20 June, DOI: 10.1017/S1462399403006318
84. Kharbanda, S. et al. (1997) Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386, 732-735, PubMed: 9109492 (Pubitemid 27193496)
85. Yuan, Z.M. et al. (1998) Regulation of Rad51 function by c-Abl in response to DNA damage. J Biol Chem 273, 3799-3802, PubMed: 9461559
86. Deutsch, E. et al. (2001) BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 97, 2084-2090, PubMed: 11264175 (Pubitemid 32239090)
87. Skorski, T. (2002) Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2, 351-360, PubMed: 12044011 (Pubitemid 37328948)
88. White, E. and Prives, C. (1999) DNA damage enables p73. Nature 399, 734-735, 737, PubMed: 10391235
89. Goldberg, Z. et al. (2002) Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. Embo J 21, 3715-3727, PubMed: 12110584 (Pubitemid 34787045)
90. Salloukh, H.F. and Laneuville, P. (2000) Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 14, 1401-1404, PubMed: 10942235 (Pubitemid 30599320)
91. Grand, F.H. et al. (1997) BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients. Leukemia 11, 1486-1492, PubMed: 9305602 (Pubitemid 27404389)
92. Verfaillie, C.M. et al. (1992) Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79, 1003-1010, PubMed: 1371077
93. Kamada, N. and Uchino, H. (1978) Chronologic sequence in appearance of clinical and laboratory findings characteristic of chronic myelocytic leukemia. Blood 51, 843-850, PubMed: 273449 (Pubitemid 8342553)
94. Bedi, A. et al. (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83, 2038-2044, PubMed: 8161775 (Pubitemid 24112713)
95. Clarkson, B. and Strife, A. (1993) Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Leukemia 7, 1683-1721, PubMed: 8231240 (Pubitemid 23347286)
96. Eaves, A.C. et al. (1998) Differences between normal and CML stem cells: potential targets for clinical exploitation. Stem Cells 16 Suppl 1, 77-83; discussion 89, PubMed: 11012149
97. Gordon, M.Y. et al. (1999) Cell biology of CML cells. Leukemia 13 Suppl 1, S65-71, PubMed: 10232368 (Pubitemid 29206383)
98. Kramer, A. et al. (2001) Proliferating status of peripheral blood progenitor cells from patients with BCR/ABL-positive chronic myelogenous leukemia. Leukemia 15, 62-68, PubMed: 11243401 (Pubitemid 32124070)
99. Hemmeryckx, B. et al. (2002) BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl. Oncogene 21, 3225-3231, PubMed: 12082638 (Pubitemid 34548093)
100. Campbell, S.L. et al. (1998) Increasing complexity of Ras signaling. Oncogene 17, 1395-1413, PubMed: 9779987 (Pubitemid 28458409)
101. Leevers, S.L. (1996) Ras signaling. In Signal Transduction (Purton, M., ed.), pp. 143-158, Chapman & Hall
102. Sakai, N. et al. (1994) Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells. Exp Cell Res 215, 131-136, PubMed: 7957661 (Pubitemid 24339183)
103. Skorski, T. et al. (1994) Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J Exp Med 179, 1855-1865, PubMed: 8195713
104. Afar, D.E. et al. (1994) Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL. Cold Spring Harb Symp Quant Biol 59, 589-594, PubMed: 7587117
105. Puil, L. et al. (1994) Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. Embo J 13, 764-773, PubMed: 8112292 (Pubitemid 24057507)
106. Gishizky, M.L., Cortez, D. and Pendergast, A.M. (1995) Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci USA 92, 10889-10893, PubMed: 7479904
107. Afar, D.E. et al. (1994) Differential complementation of Bcr-Abl point mutants with c-Myc. Science 264, 424-426, PubMed: 8153630 (Pubitemid 24178905)
108. Cortez, D., Kadlec, L. and Pendergast, A.M. (1995) Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol 15, 5531-5541, PubMed: 7565705
109. Goga, A. et al. (1995) Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82, 981-988, PubMed: 7553858
110. Mandanas, R.A. et al. (1993) Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells. Blood 82, 1838-1847, PubMed: 7691239 (Pubitemid 23278775)
111. Xie, S. et al. (2001) Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 20, 6188-6195, PubMed: 11593427 (Pubitemid 32964431)
112. Carlesso, N., Frank, D.A. and Griffin, J.D. (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183, 811-820, PubMed: 8642285 (Pubitemid 26113953)
113. Chai, S.K., Nichols, G.L. and Rothman, P. (1997) Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159, 4720-4728, PubMed: 9366395 (Pubitemid 127471006)
114. Ilaria, R.L., Jr. and Van Etten, R.A. (1996) P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271, 31704-31710, PubMed: 8940193 (Pubitemid 26408636)
115. Sexl, V. et al. (2000) Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl-and bcr/abl-induced transformation are independent of stat5. Blood 96, 2277-2283, PubMed: 10979977
116. Horita, M. et al. (2000) Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191, 977-984, PubMed: 10727459
117. Sattler, M. et al. (1996) The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene 12, 839-846, PubMed: 8632906
118. Lioubin, M.N. et al. (1996) p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev 10, 1084-1095, PubMed: 8654924
119. Wisniewski, D. et al. (1999) A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93, 2707-2720, PubMed: 10194451 (Pubitemid 29181204)
120. Skorski, T. et al. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. Embo J 16, 6151-6161, PubMed: 9321394 (Pubitemid 27458335)
121. del Peso, L. et al. (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689, PubMed: 9381178 (Pubitemid 27464966)
122. Franke, T.F., Kaplan, D.R. and Cantley, L.C. (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88, 435-437, PubMed: 9038334 (Pubitemid 27154408)
123. Evans, C.A. et al. (1995) Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. J Cell Sci 108, 2591-2598, PubMed: 7593300
124. Perrotti, D. et al. (2000) BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CbetaII-dependent pathway. Mol Cell Biol 20, 6159-6169, PubMed: 10913197 (Pubitemid 30613063)
125. Perrotti, D. et al. (2002) BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30, 48-58, PubMed: 11753385
126. Iervolino, A. et al. (2002) hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol 22, 2255-2266, PubMed: 11884611 (Pubitemid 34224631)
127. Wisniewski, D. et al. (1996) c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia. Leukemia 10, 229-237, PubMed: 8637231
128. Moore, S. et al. (1998) Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells. Blood 92, 2461-2470, PubMed: 9746786 (Pubitemid 28452989)
129. Hallek, M. et al. (1996) Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol 94, 5-16, PubMed: 8757502 (Pubitemid 26232533)
130. Zhao, R.C., Jiang, Y. and Verfaillie, C.M. (2001) A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector. Blood 97, 2406-2412, PubMed: 11290604 (Pubitemid 32291487)
131. Sill, H., Goldman, J.M. and Cross, N.C. (1995) Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85, 2013-2016, PubMed: 7718873
132. Nanjangud, G. et al. (1994) Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis. Leuk Res 18, 385-392, PubMed: 8182930 (Pubitemid 24154225)
133. Cuenco, G.M. and Ren, R. (2001) Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 20, 8236-8248, PubMed: 11781838 (Pubitemid 34038211)
134. Dash, A.B. et al. (2002) A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc Natl Acad Sci USA 99, 7622-7627, PubMed: 12032333 (Pubitemid 34568741)
135. Sawyers, C.L., Callahan, W. and Witte, O.N. (1992) Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70, 901-910, PubMed: 1525828
136. Bossone, S.A. et al. (1992) MAZ, a zinc finger protein, binds to c-MYC and C2 gene sequences regulating transcriptional initiation and termination. Proc Natl Acad Sci USA 89, 7452-7456, PubMed: 1502157
137. Ahuja, H. et al. (1989) Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86, 6783-6787, PubMed: 2771957 (Pubitemid 19236343)
138. Feinstein, E. et al. (1991) p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci USA 88, 6293-6297, PubMed: 2068108 (Pubitemid 21914932)
139. Feinstein, E. et al. (1992) Initiation and progression of chronic myelogenous leukemia. Leukemia 6 Suppl 1, 37-43, PubMed: 1548934
140. Foti, A. et al. (1991) Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis. Blood 77, 2441-2444, PubMed: 2039825
141. Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature 358, 15-16, PubMed: 1614522
142. Ahuja, H. et al. (1991) The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 87, 2042-2047, PubMed: 2040694
143. Towatari, M. et al. (1991) Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenous leukemia. Blood 78, 2178-2181, PubMed: 1932738
144. Dou, Q.P. et al. (1999) Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 289, 781-790, PubMed: 10215653 (Pubitemid 29191232)
145. Soligo, D. et al. (2001) The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 113, 126-135, PubMed: 11328292 (Pubitemid 32423313)
146. Tauchi, T., Yoshimura, A. and Ohyashiki, K. (2001) CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway. Exp Hematol 29, 356-361, PubMed: 11274764 (Pubitemid 32220128)
147. Albrecht, T. et al. (1996) Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 95, 501-507, PubMed: 8943891 (Pubitemid 26388691)
148. Amos, T.A. et al. (1995) Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 91, 387-393, PubMed: 8547080
149. Vallejos, C.S. et al. (1973) Biological effects of repeated leukapheresis of patients with chronic myelogenous leukemia. Blood 42, 925-933, PubMed: 4519104
150. Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials. Chronic myeloid leukemia trialists' collaborative group. Br J Haematol 110, 573-576, PubMed: 10997966
151. Goldman, J.M. and Druker, B.J. (2001) Chronic myeloid leukemia: current treatment options. Blood 98, 2039-2042, PubMed: 11567987
152. Mughal, T.I. et al. (2001) Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse. Br J Haematol 115, 569-574, PubMed: 11736937 (Pubitemid 34015646)
153. Savage, D.G. and Goldman, J.M. (1998) Allografting for chronic myelogenous leukaemia. In Medical Management of Chronic Myelogenous Leukemia (Talpaz, M. and Kantarjian, H., eds), pp. 215-218, Marcell Dekker
154. Gratwohl, A. et al. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352, 1087-1092, PubMed: 9798583 (Pubitemid 28448513)
155. Goldman, J. (1998) Hematopoietic stem cell transplantation. Curr Opin Hematol 5, 417-418, PubMed: 9814649 (Pubitemid 28521511)
156. Carlo-Stella, C. et al. (1988) Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM). Blood 72, 1293-1299, PubMed: 3139105 (Pubitemid 18265894)
157. Gordon, M.Y. et al. (1998) Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM. J Clin Invest 102, 710-715, PubMed: 9710439 (Pubitemid 28399603)
158. Bhatia, R., McCarthy, J.B. and Verfaillie, C.M. (1996) Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 87, 3883-3891, PubMed: 8611716 (Pubitemid 26129618)
159. Bhatia, R. et al. (1994) Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest 94, 384-391, PubMed: 7518835
160. Dowding, C. et al. (1991) Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 78, 499-505, PubMed: 1906352
161. Cornelissen, J.J. et al. (1998) An in vitro model for cytogenetic conversion in CML. Interferon-alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture. J Clin Invest 102, 976-983, PubMed: 9727066 (Pubitemid 28419242)
162. Luchetti, F. et al. (1998) The K562 chronic myeloid leukemia cell line undergoes apoptosis in response to interferon-alpha. Haematologica 83, 974-980, PubMed: 9864915 (Pubitemid 29039464)
163. Selleri, C. et al. (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89, 957-964, PubMed: 9028327 (Pubitemid 27121289)
164. Fujii, S. (2000) Role of interferon-alpha and clonally expanded T cells in the immunotherapy of chronic myelogenous leukemia. Leuk Lymphoma 38, 21-38, PubMed: 10811445 (Pubitemid 30224320)
165. Talpaz, M. et al. (1983) Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med 99, 789-792, PubMed: 6580836 (Pubitemid 14248407)
166. Talpaz, M. et al. (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62, 689-692, PubMed: 6192858 (Pubitemid 13001704)
167. Hochhaus, A. et al. (2000) Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 95, 62-66, PubMed: 10607685 (Pubitemid 30017225)
168. Kantarjian, H.M. et al. (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 122, 254-261, PubMed: 7825760
169. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst 89, 1616-1620, PubMed: 9362160
170. Lindauer, M. and Fischer, T. (2001) Interferon-alpha combined with cytarabine in chronic myelogenous leukemia-clinical benefits. Leuk Lymphoma 41, 523-533, PubMed: 11378570 (Pubitemid 32717306)
171. Cortes, J. and O'Brien, S. (2000) A guide to the use of interferon-alpha in the management of chronic myelogenous leukaemia. Biodrugs 14, 211-220
172. Buchdunger, E. et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56, 100-104, PubMed: 8548747
173. Heinrich, M.C. et al. (2000) Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932, PubMed: 10910906 (Pubitemid 30618049)
174. Okuda, K. et al. (2001) ARG tyrosine kinase activity is inhibited by STI571. Blood 97, 2440-2448, PubMed: 11290609 (Pubitemid 32291492)
175. Druker, B.J. et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344, 1031-1037, PubMed: 11287972 (Pubitemid 32267972)
176. Druker, B.J. et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344, 1038-1042, PubMed: 11287973 (Pubitemid 32267973)
177. Kantarjian, H. et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346, 645-652, PubMed: 11870241 (Pubitemid 34815868)
178. Talpaz, M. et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99, 1928-1937, PubMed: 11877262 (Pubitemid 34525471)
179. Sawyers, C.L. et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-3539, PubMed: 11986204 (Pubitemid 34534519)
180. Hughes, T. et al. (2002) Molecular responses to Imatinib (STI571) or interferon + Ara-C as initial therapy for CML; results in the IRIS Study. Blood 100, 345a
181. Druker, B.J. et al. (2002) STI571 (Gleevec, Glivec, Imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CML: results of an international randomised study. Proceedings of the American Society of Clinical Oncology 21, Abstract 1
182. O'Brien, S.G. et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348, 994-1004, PubMed: 12637609 (Pubitemid 36302244)
183. Graham, S.M. et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325, PubMed: 11756187
184. le Coutre, P. et al. (2000) Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95, 1758-1766, PubMed: 10688835 (Pubitemid 30120840)
185. Mahon, F.X. et al. (2000) Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070-1079, PubMed: 10910924 (Pubitemid 30616875)
186. Weisberg, E. and Griffin, J.D. (2000) Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95, 3498-3505, PubMed: 10828035 (Pubitemid 30428483)
187. Gorre, M.E. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880, PubMed: 11423618 (Pubitemid 32743979)
188. Branford, S. et al. (2002) High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475, PubMed: 11964322 (Pubitemid 34525335)
189. Roche-Lestienne, C. et al. (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018, PubMed: 12130516 (Pubitemid 34832631)
190. Roumiantsev, S. et al. (2002) Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99, 10700-10705, PubMed: 12149456
191. Shah, N.P. et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125, PubMed: 12204532 (Pubitemid 41039112)
192. Azam, M., Latek, R.R. and Daley, G.Q. (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843, PubMed: 12654249 (Pubitemid 36378885)
193. Marktel, S. et al. (2002) Chronic myeloid leukaemia in chronic phase responding to imatinib: the occurence of additional cytogenetic markers predicts disease progression. Blood 100, 3104a
194. Schoch, C. et al. (2002) Occurrence of additional chromosome aberrations in chronic myeloid leukemia treated with imatinib mesylate. Blood 100, 1410a
195. Hoover, R.R. et al. (2002) Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 100, 1068-1071, PubMed: 12130526 (Pubitemid 34832641)
196. Klejman, A. et al. (2002) Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 21, 5868-5876, PubMed: 12185586 (Pubitemid 35007237)
197. Vigneri, P. and Wang, J.Y. (2001) Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 7, 228-234, PubMed: 11175855 (Pubitemid 32148491)
198. Matsuguchi, T. et al. (1994) Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem 269, 5016-5021, PubMed: 7508932
199. Carpino, N. et al. (1997) p62(dok): a constitutively tyrosine- phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 88, 197-204, PubMed: 9008160
200. Druker, B. et al. (1992) Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood 79, 2215-2220, PubMed: 1571536
201. Skorski, T. et al. (1995) C-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res 55, 2275-2278, PubMed: 7757976
202. Oda, T. et al. (1994) Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269, 22925-22928, PubMed: 8083188 (Pubitemid 24283264)
203. de Jong, R. et al. (1995) Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 270, 21468-21471, PubMed: 7545163
204. Feller, S.M., Knudsen, B. and Hanafusa, H. (1994) c-Abl kinase regulates the protein binding activity of c-Crk. Embo J 13, 2341-2351, PubMed: 8194526
205. Skorski, T. et al. (1995) Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86, 726-736, PubMed: 7606002
206. Neshat, M.S. et al. (2000) The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and-independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol 20, 1179-1186, PubMed: 10648603 (Pubitemid 30069238)
207. Amarante-Mendes, G.P. et al. (1998) Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 16, 1383-1390, PubMed: 9525737 (Pubitemid 28151845)
208. Hoover, R.R. et al. (2001) Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 20, 5826-5835, PubMed: 11593388 (Pubitemid 32937952)
209. Salgia, R. et al. (1995) CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 270, 29145-29150, PubMed: 7493940 (Pubitemid 3016899)
210. Afar, D.E. et al. (1997) Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 6, 773-782, PubMed: 9208849 (Pubitemid 27305739)
211. Gotoh, A. et al. (1995) Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol 23, 1153-1159, PubMed: 7556524
212. Salgia, R. et al. (1995) Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 11, 1149-1155, PubMed: 7566975
213. Ernst, T.J., Slattery, K.E. and Griffin, J.D. (1994) p210Bcr/Abl and p160v-Abl induce an increase in the tyrosine phosphorylation of p93c-Fes. J Biol Chem 269, 5764-5769, PubMed: 8119916
214. Gotoh, A. et al. (1994) Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase. Leukemia 8, 115-120, PubMed: 8289476
215. Matsuguchi, T. et al. (1995) Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. Embo J 14, 257-265, PubMed: 7530656
216. Tauchi, T. et al. (1994) SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase. J Biol Chem 269, 15381-15387, PubMed: 8195176 (Pubitemid 24198392)